Patient Perspective on Cross-Linking

Learn more about the importance of early diagnosis and treatment from a keratoconus patient and her treating physician.

A General Overview

Corneal cross-linking is a minimally invasive outpatient procedure that combines the use of Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and the KXL® system for the treatment of progressive keratoconus.

Corneal Cross-Linking:
  • Creates new corneal collagen cross-links
  • Results in a shortening and thickening of the collagen fibrils
  • Leads to the stiffening of the cornea

Top Questions to Ask Your Eye Doctor Download PDF

FDA Approval

The first and only therapeutic products for corneal cross-linking which have been FDA approved to treat progressive keratoconus.

In April 2016, the FDA approved Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and the KXL® System for corneal cross-linking, a minimally invasive outpatient procedure that combines the use of Vitamin B2 eye drops and ultra-violet (UV) light.

The approval of Photrexa Viscous, Photrexa and the KXL System offers an effective treatment for patients who, until recently, had no therapeutic options to limit the progression of this sight-threatening disease.

Cross-Linking

Learn more about this outpatient procedure

View our Living with Keratoconus Patient Brochure.

Patient FAQs

Discover answers to the most common questions surrounding cross-linking

Visit the Patient FAQ Section to learn more.

It is estimated that...

1 Out of Every 2,000

persons in the general population have Keratoconus1

You can find more information from the National Keratoconus Foundation.

1. Kennedy R. H., Bourne W. M., Dyer J. A. A 48-year clinical and epidemiologic study of keratoconus. The American Journal of Ophthalmology. 1986;101(3):267–273. doi: 10.1016/0002-9394(86)90817-2.

Corneal cross-linking provides patients a much-needed option to treat this debilitating disease. Patients suffering from progressive keratoconus can now receive a therapeutic treatment that has been rigorously tested and approved."

Mary Prudden, Executive Director for the National Keratoconus Foundation

What are Patients Saying? View Stories

Learn More Through Our Facebook Page

2 weeks ago

Living with KC

Looking for another great #keratoconus resource? Visit the National Keratoconus Foundation's website and follow them on Facebook for additional information on KC and upcoming events! www.nkcf.org/ ... See MoreSee Less

View on Facebook

2 weeks ago

Living with KC

Insurance update! 63 total insurance carriers are now covering #crosslinking! ... See MoreSee Less

View on Facebook

Learn More Through Our Twitter Page

Amritpal was only 16 when he was diagnosed with #keratoconus by @drpeterhersh He recently spoke with the National Keratoconus Foundation about his #KCJourney and finding an appropriate treatment option. Read it here: https://t.co/8gkfh9JD9t

Want to learn more about #keratoconus? William Dupps, MD, PhD, of the @ClevelandClinic, discusses some of the signs and available treatment options. https://t.co/n3s3YW9fQG

New to #LivingWithKC? We're a safe & inclusive patient community that supports those on a #KCJourney. Visit our website to learn more! https://t.co/Ebcz0WysCg

Looking for another great #keratoconus resource? Visit the National Keratoconus Foundation's website and follow them on Facebook for additional information on KC and upcoming events! https://t.co/rvhCfaUC4o

Insurance update! 63 total insurance carriers are now covering #crosslinking!

Load More...

Learn More Through Our Instagram

MA-00687B